An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
background
Lung cancer is the leading global cause of cancer-related mortality [1] . In non-small-cell lung cancer (NSCLC), first-line platinum-based doublet chemotherapy is associated with modest survival benefits and improvements in disease-related symptoms and quality of life (QoL) [2] . Docetaxel (Taxotere, Sanofi-Aventis, Paris, France), as second-line treatment, is associated with prolonged survival compared with best supportive care [3] , while pemetrexed has similar efficacy to docetaxel with fewer side-effects [4] . The NCIC Clinical Trials Group (NCIC CTG) BR.21 trial confirmed a survival benefit with the oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) erlotinib compared with placebo after failure of at least one prior chemotherapy regimen [5] .
Three phase III trials have compared the oral EGFR TKI gefitinib (250 mg/day) with docetaxel (60-75 mg/m 2 ). In the ISTANA trial (Iressa as Second-line Therapy in Advanced NSCLC) [6] , gefitinib was associated with a higher overall response rate, longer progression-free survival (PFS) and fewer grade 3/4 adverse events than docetaxel. In V-15-32 [7] , although the trial did not meet its prespecified endpoint of noninferiority in overall survival (OS), there was no significant difference between the groups (P = 0.330), and gefitinib demonstrated greater QoL improvement. The INTEREST trial (IRESSA NSCLC Trial Evaluating Response and Survival against Taxotere) randomized 1466 pretreated patients to gefitinib or docetaxel [8] and met its primary objective, demonstrating noninferiority of OS for gefitinib versus docetaxel. PFS and objective response rate were similar in both arms (Table 1) . Grade 3/4 toxic effects were less common with gefitinib compared with chemotherapy (8.5% versus 40.7%), and significantly more patients experienced clinically relevant improvements in QoL with gefitinib.
The equivalent efficacy, better toxicity profile and greater improvements in QoL suggest that gefitinib is a valid alternative to chemotherapy for the second-or third-line treatment of advanced NSCLC across all patient subgroups. However, treatment of NSCLC has come under scrutiny because of associated high costs with only perceived modest associated benefits. Therefore, we conducted an analysis of the INTEREST trial to determine the direct medical costs of gefitinib compared with docetaxel. Because noninferiority was demonstrated, a cost-consequence analysis was carried out.
methods
We conducted a retrospective cost-consequence analysis comparing docetaxel with gefitinib for the treatment of NSCLC using data from INTEREST provided by AstraZeneca (Iressa, AstraZeneca, Macclesfield, UK) including study treatment (mean doses, duration of treatment), PFS and OS data, National Cancer Institute Common Toxicity Criteria version 2.0 adverse event data (incidence), supportive therapy including mean number of red blood cell (RBC) transfusions, percentage of patients treated with granulocyte colony-stimulating factor (g-CSF) per arm and the percentage of patients receiving radiotherapy. The analysis was conducted from the perspective of the Canadian public health care system; hence, only direct costs were included. Resource utilization and costs were determined from the start of study treatment until discontinuation of study drug. Costs, determined at Princess Margaret Hospital/University Health Network (PMH/UHN), are presented in 2008 Canadian dollars (CAD$). Where appropriate, costs were inflated to 2008 CAD$ using the Canadian Consumer Price Index (http://www.bankofcanada.ca/en/cpi.html). Resource utilization for toxicity management was modeled using current literature, practice guidelines and expert opinion where appropriate.
The measures of health effectiveness, derived from the INTEREST trial, were mean/median survival, toxicity rates and QoL scores. With mean/ median survival in both treatment arms less than 1 year, discounting was not undertaken.
determination of cost study treatment PMH pharmacy acquisition cost was used for docetaxel. Preparation and administration costs, including nursing, pharmacist and pharmacy technician costs, were determined by a time-in-motion study [9] . Chemotherapy visit costs were determined using the attributable hotel costs, including facility and overhead costs.
Gefitinib 
additional costs
Canadian Blood Services provided the cost of a unit of RBCs (Barbara Hannach, personal communication). This was added to administration costs derived from staff salaries and attributed hotel costs. Utilization of transfusions was based on the incidence of grade 3/4 anemia, as individual data were not available. The proportion of patients who received gCSF and radiation was provided. A mean cost was generated per patient for gCSF use, modeled on current practice (one course of filgrastim 300 lg/day for 7 days, with subsequent chemotherapy dose reduction given the palliative setting), and PMH pharmacy cost including dispensing fee. Radiation costs included per fraction and treatment review costs. Standard palliative dosing and fractionation protocols were assumed, and 
determination of resource utilization study drug and concomitant medications
The mean administered dose per patient and duration of treatment per arm were obtained from the INTEREST trial. Dexamethasone premedication and antiemetic therapies were included for docetaxel (http://www.sanofi-aventis.ca/products/ en/taxotere.pdf).
routine investigations
Patients in both arms of INTEREST had similar routine investigations (three-weekly bloodwork and outpatient assessment, six-weekly imaging). For each cycle of docetaxel, it was assumed patients had bloodwork, chest X-ray and outpatient assessment. For gefitinib-treated patients, the same was assumed to occur at baseline, at 3 weeks, and then at 9-week intervals, better reflecting current clinical practice.
adverse events
A comprehensive list of 'adverse event terms' by 'System Organ Class' from INTEREST was available. Only grade 3/4 adverse events were assumed to incur significant costs and included in the analysis. These were classified into ICD-10 coded groupings. Resource utilization and costs were modeled for these groups, with ER review and hospital admission assumed for all grade 4 non-hematologic events and febrile neutropenia. All severe events were assumed to occur only once per treatment course, assuming physicians would modify treatment to minimize further toxicity.
statistical analyses
The mean cost of study drug is the product of the unit cost and the mean dose administered. Medical resource costs (e.g. radiotherapy) were determined by multiplying the unit cost of the projected resource by the proportion of patients requiring the intervention. A one-way sensitivity analysis was conducted to determine the impact of varying individual costs 620%. In addition, pemetrexed chemotherapy, a second-line treatment option in nonsquamous NSCLC, was modeled as an alternate comparator, with efficacy, toxicity and resource utilization estimates taken from a comparative trial with docetaxel [4] . utility and quality-adjusted survival QoL was assessed using Functional Assessment of Cancer Therapy -Lung [10] , Trial Outcome Index and Lung Cancer Subscales. The FACT-L is a self-report instrument which measures multidimensional quality of life. Utility data were not collected, and there are few validated methods to transpose QoL scores into utility values. In an exploratory analysis, we utilized the methodology of Kind and Macran [11] to derive utility values from FACT-L scores. Utility values determined for 10 items in the FACT-L were converted into a single summary score [11] for patients with data available at baseline and at least one additional time point. The area under the curve for each arm was generated until 9 weeks on treatment ('median PFS). Generalized estimating equations were used in a repeated measures analysis to compare utility and quality-adjusted survival between groups over this period. Overall differences between treatment arms were evaluated via interaction effects between 'group' and 'time'. The 'last observation carried forward' method was used to account for missing values [12, 13] .
Data provided for the EGFR-activating mutation-positive (M+) subgroup were explored. A Markov model consisting of stable, responsive and progressive disease was generated (treatment until progression, hence 'death' state not included) to determine total and quality-adjusted costs until progression. Clinical inputs (e.g. drug costs and toxicity costs) were based on data provided from the INTEREST trial. Utilities generated from FACT-L scores were incorporated into the model, and a disutility applied upon progression. A 10 000 patient Monte Carlo simulation was run to incorporate utilities and determine the preferable treatment strategy.
results
In INTEREST, 1466 patients were randomly assigned to receive gefitinib (n = 733) or docetaxel (n = 733) [8] . Patients had locally advanced or metastatic NSCLC that had progressed/recurred following one to two prior chemotherapy regimens including platinum. Median survival was 7.6 months for gefitinib and 8.0 months for docetaxel (hazard ratio 1.020, 96% confidence interval 0.905-1.150, P = 0.73), meeting the predefined criterion for noninferiority. Median PFS was 2.2 and 2.7 months for gefitinib and docetaxel, respectively. Mean duration of treatment was 134.5 days for gefitinib (median 73), and 91.5 days for docetaxel (median 84). More patients had clinically relevant improvement in QoL with gefitinib than with docetaxel (Table 1) .
Estimated resource utilization and unit costs are summarized in Tables 2 and 3 . The mean total cost per patient from treatment start until drug discontinuation was $13 407 for gefitinib and $8246 for docetaxel, giving an incremental mean cost of $5161 (Table 4) . Drug cost was the major contributor to overall cost in both arms, accounting for 76% and 47% of total cost in the gefitinib and docetaxel arms, respectively. Considering all costs, there is near cost parity per 3-week cycle between the arms (Table 4) , with an incremental cost of $132 for gefitinib over docetaxel. The total mean incremental cost of gefitinib over docetaxel in this analysis reflects longer mean duration of therapy. The discrepancy between the mean number of cycles (4.2) and the actual mean dose of docetaxel administered (304.8 mg) indicates a significant proportion of patients required dose reduction.
sensitivity analyses
Varying the estimates of major cost drivers by 620% did not change the direction of the cost difference in any of the sensitivity analyses (Figure 1 ). The incremental cost was most sensitive to changes in gefitinib cost, ranging from an additional $3113 to $7207 per patient. Conducting routine investigations every 21 days per study protocol in the gefitinib arm versus less frequent investigations in current practice resulted in increased costs, an additional $1149 per patient because of longer duration of gefitinib therapy (additional $179 per cycle) for a total incremental cost of $6310 per patient. Substituting pemetrexed for docetaxel as the comparator yielded higher drug costs for an estimated four cycles of therapy ($16 800). Costs for grade 3/4 toxicity management, including transfusion and growth factor administration, were adjusted based on the comparative trial of docetaxel and pemetrexed. The resulting total cost per patient treated with pemetrexed was estimated at $20 347, with a cost per cycle estimated at $5086. This results in a total incremental cost of pemetrexed over gefitinib of $6940, or $2991 per cycle.
utility and quality-adjusted survival
Approximately half the patients enrolled in INTEREST had QoL data available for analysis (Supplemental Figure S1 , available at Annals of Oncology online). Estimated mean utilities at each time point are shown in Figure 2 [11] . There was no difference in mean utilities, nor in quality-adjusted survival, between treatment arms.
EGFR mutation-positive subgroup
Data for 44 patients in the INTEREST trial with activating EGFR mutations were provided, 22 in each treatment arm. In exploratory analysis, median PFS was 7.0 months, mean duration of therapy was 295 days (median 248) and mean utility until progression was 0.291 (median 0.312) for gefitinib. For docetaxel, mean PFS was 4.1 months, mean (and median) number of cycles was 4 and mean utility was 0.225 (median 0.203). In our Markov model, run for a year, the total mean cost estimated per patient until progression was $12 753 in the gefitinib arm and $6,922 in the docetaxel arm, predominantly driven by drug cost and duration of therapy in the gefitinib arm, and both drug and toxicity costs in the docetaxel arm. Mean quality-adjusted cost until progression was $43 825 on gefitinib, $30 764 on docetaxel. In a 10 000 patient Monte Carlo simulation incorporating utilities, gefitinib was the preferred treatment 74% of the times.
discussion
Despite improvements in patient outcome with molecularly targeted agents for cancer, the cost and budgetary impact of these therapies on society is of concern. This analysis found that gefitinib is associated with modestly higher treatment costs than docetaxel in the setting of advanced NSCLC in the INTEREST trial. Drug cost was the major contributor to overall cost in both arms. The incremental drug cost per patient of gefitinib over docetaxel was $6755, partly offset by costs for infusion visits, supportive medications and higher incidence of grade 3/4 toxicity with docetaxel. Since the incremental cost of gefitinib over docetaxel per 21-day cycle is only $132.00, the greatest impact on cost difference is the duration of therapy. In INTEREST, treatment was until progression or at investigator discretion. The mean number of docetaxel cycles administered was 4, while patients were randomly assigned to gefitinib remained on treatment for a longer time (mean ' 134 days). Some patients (docetaxel n = 15; gefitinib n = 146) remained on treatment despite progression by RECIST, presumably those deemed to be deriving clinical benefit, as per protocol. While we potentially overestimate the incremental cost difference modestly by including those treated beyond progression, this likely reflects actual clinical practice.
It is reasonable to expect that orally administered gefitinib, with its greater QoL benefit and milder toxicity profile than docetaxel, would be valued more highly and therefore have Routine bloods: complete blood count, biochemistry. BSA, body surface area; CXR: chest X-ray; CT TA, computed tomography scan thorax and abdomen; CAD$, Canadian dollars; g-CSF, granulocyte colony-stimulating factor; RBC, red blood cell. original article Annals of Oncology a greater utility. A Mexican cost-utility analysis of gefitinib versus docetaxel supports this assumption [14] . In that analysis, probabilities were generated for adverse events and life expectancy using published INTEREST data. Based on utility scores in the literature [15] , quality-adjusted survival was estimated to be greater for gefitinib. However, compared with our analysis, that study reported a much higher overall cost of docetaxel therapy ($18 230 USD) and a lower cost per cycle for gefitinib ($1217 USD). The methodology used in our analysis of transposing FACT-L scores to utility values did not reflect the difference in QoL improvement seen between the treatment arms. While missing data may contribute to this finding, it is more likely that our results support concerns about the validity of conversion algorithms, and the challenges of deriving quality-adjusted survival retrospectively from trial data in general [16] . Incorporating utility measurement prospectively into randomized clinical trials should be encouraged for trials of novel cancer therapies. Tornado plot: sensitivity analysis of incremental cost based on 20% addition/discount. *Costs of main drivers of incremental costs were increased/ decreased by 20% and the effect on mean incremental cost difference is represented. For investigations, the modeled (per current practice) and trial-protocol driven costs and effect on mean incremental cost is shown. Patients with nonsquamous NSCLC have an increasing number of treatment options in the second-line setting, including pemetrexed. Although exploratory, our modeling exercise suggests that gefitinib until progression may be less costly than pemetrexed. We have not included erlotinib in our analysis, and randomized data comparing erlotinib to pemetrexed or docetaxel in the second-line setting are pending. Patient selection for EGFR TKI therapy has also emerged as important in the first-line setting, where gefitinib is associated with better PFS and QoL improvement than platinum-based chemotherapy in EGFR M+ patients [17] . While only small numbers of M+ patients were available for an exploratory subgroup analysis from INTEREST, gefitinib was associated with longer PFS and evidence of better qualityadjusted time to progression, although a trend to higher cost than docetaxel.
This study is limited by the lack of individual patient utilization data collected prospectively. We modeled patterns of resource use for toxicity management based on practice; however, these costs are relatively small and unlikely to impact on the final result significantly. Also, we were unable to capture costs after treatment discontinuation, but given the similar time to progression and survival in both arms, these are likely similar. Third-line therapy in the INTEREST trial was frequently used, with 46% of patients in the gefitinib arm crossing over to chemotherapy after progression (31% receiving docetaxel). Similarly in the docetaxel arm, 37% of patients subsequently received gefitinib or erlotinib. Thus, it is important to recognize that many patients who receive secondline chemotherapy subsequently receive third-line EGFR TKI therapy. Based on this, it is reasonable to assume that overall treatment costs or budget impact may be similar, irrespective of which agent is administered first. Some argue that patients should receive cytotoxic chemotherapy earlier, when better able to tolerate side-effects, and others, that patients should receive the agent with the least toxicity and strongest QoL data initially, reserving chemotherapy for the third-line setting in fit patients. The INTEREST study results suggest that either sequence is acceptable.
To date, few studies report gefitinib costs in lung cancer, with more data published on costs of erlotinib. Two Canadian studies compared erlotinib with best supportive care, differing from our analysis where an active comparator was used. These reported incremental cost-effectiveness increments of $71 018 [18] and $94 638 (CAD$) [19] for erlotinib. A British study estimated that per patient, erlotinib (£13 175) was more costeffective than docetaxel (£13 312) in the second-line setting, although there are no clinical data available currently to support this comparison [20] . Ramsey et al. [21] estimated a modest budget impact of introducing erlotinib as second-or third-line therapy for patients with advanced NSCLC. Erlotinib cost was offset by reduced administration and toxicity costs when compared with pemetrexed and docetaxel. Chouaid et al. [22] considered the economic impact of gefitinib for refractory NSCLC using a Markov model-based decision analysis approach in 106 patients. Mean global costs per patient and the costs of different management phases were determined (total cost €39 979). First-and second-line treatment accounted for 29.5% and 44.1% of the total cost, respectively. Gefitinib cost represented only 10.7% and had little impact on total cost in sensitivity analyses. None of these studies considered patient preferences [23] or indirect costs.
Economic endpoints are becoming increasingly important in the approval of novel agents. This analysis, utilizing data from the INTEREST trial, confirmed an incremental difference in cost for gefitinib compared with docetaxel in the treatment of patients with pretreated, advanced NSCLC. However, gefitinib has advantages in terms of convenience of an oral therapy, decreased time spent in hospital receiving treatment, a better toxicity profile and clinically relevant improvements in QoL. Thus, in the setting of similar efficacy, the use of EGFR TKIs as second-line therapy is unlikely to increase overall costs significantly in several jurisdictions, and should be considered for selected patients. [12] . *Utilities generated using the Kind and Macran algorithm. Not significant for treatment interaction at 9 weeks (P = 0.613).
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